newsfilter
← Latest News
GlobeNewswire·

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award

  • MBX Biosciences appointed Mark R. Soued as Chief Commercial Officer effective May 1, 2026.
  • Soued brings over two decades of commercial leadership experience from Alnylam Pharmaceuticals & Pfizer.
  • At Alnylam, Soued served as Senior Vice President & Head of US, leading the launch of AMVUTTRA® in ATTR cardiomyopathy.
  • Prior to Alnylam, Soued held senior roles at Pfizer including Regional President for North America's Hospital Business Unit & led the US launch of VYNDAQEL®/VYNDAMAX®.
  • MBX granted Soued an inducement equity award of 160,000 non-qualified stock options with an exercise price of $29.78 per share.
  • The stock options have a 10-year term & vest over four years, starting with 25% on the one-year anniversary of April 29, 2026.
  • MBX Biosciences is advancing a pipeline including canvuparatide (Phase 3 for chronic hypoparathyroidism), an obesity portfolio (Phase 1), & imapextide (Phase 2 for post-bariatric hypoglycemia).
  • The company is based in Carmel, Indiana & focuses on proprietary Precision Endocrine Peptides™ for endocrine & metabolic disorders.